Best Healthcare Market Research Companies in Poland (2026 Guide)
An independent guide to the leading healthcare market research companies operating in Poland for 2026. This guide profiles 5 specialist firms across pharmaceutical primary research, AOTMiT health technology assessment support, NFZ payer research, physician and KOL engagement, and HEOR — comparing capabilities and Poland-specific expertise to help you select the right healthcare research partner in the largest pharmaceutical market in Central and Eastern Europe.
Published 2026-06-11 · By BioNixus Research Team
5
Firms Profiled
€10B+
Pharma Market
AOTMiT
HTA Agency
8
FAQs Answered
Best Healthcare Market Research Companies in Poland (2026)
The following healthcare market research companies have demonstrated operations or project delivery in Poland as of 2026, covering pharmaceutical primary research, AOTMiT/NFZ HTA and payer support, HEOR, and physician and patient research across Poland and the CEE region:
- 1BioNixus — Best for: pharmaceutical U&A, KOL mapping, physician surveys, AOTMiT/NFZ HTA and market access support, HEOR, Polish KOL networks, and CEE regional strategy — Poland execution with global methodology standards
- 2IQVIA Poland — Best for: IMS Poland pharma prescription data, Polish RWE, sales force effectiveness, and URPL/AOTMiT regulatory analytics
- 3Ipsos Healthcare Poland — Best for: large-scale quantitative and qualitative healthcare research, HCP and patient surveys in Poland
- 4Kantar (Poland/CEE) — Best for: patient research, consumer health tracking, health behaviour studies, and brand health across Poland and CEE
- 5Euromonitor International — Best for: syndicated Poland market sizing, country reports, competitive landscape intelligence, and CEE category forecasts for consumer health
Poland Healthcare Market Research Landscape 2026
Poland is the largest pharmaceutical market in Central and Eastern Europe (CEE), valued at over €10 billion and growing steadily, driven by strong economic performance, EU membership, and increasing healthcare investment. Warsaw is the primary pharma hub, hosting multinational regional headquarters and CEE offices from major pharmaceutical companies alongside a significant domestic pharmaceutical manufacturing sector. Poland's large population of approximately 38 million, combined with its central European geographic position, makes it a bellwether market for broader CEE pharmaceutical strategies.
Poland's healthcare system operates through the NFZ (Narodowy Fundusz Zdrowia — National Health Fund), which is the primary public payer responsible for pharmaceutical reimbursement decisions. Pharmaceutical pricing and reimbursement in Poland is governed by the Ministry of Health (Ministerstwo Zdrowia — MZ) following HTA assessment by AOTMiT (Agencja Oceny Technologii Medycznych i Taryfikacji — the Agency for Health Technology Assessment and Tariff System). URPL (Urząd Rejestracji Produktów Leczniczych, Wyrobów Medycznych i Produktów Biobójczych — the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products) governs national product registration alongside EMA centralised procedures. Understanding the interaction between AOTMiT HTA assessment, MZ pricing decisions, and NFZ reimbursement listing is central to Poland pharmaceutical market access strategy.
Poland has invested significantly in its pharmaceutical and clinical research infrastructure, becoming one of Europe's most active clinical trial markets and a key location for CEE-wide studies. The country's strong generic pharmaceutical manufacturing sector — with companies like Polpharma, Adamed, and Gedeon Richter Poland — creates active competitive intelligence demand. Poland's EU membership means full alignment with EMA regulatory standards, while AOTMiT's HTA methodology increasingly aligns with EUnetHTA frameworks. For healthcare research buyers, Poland represents a market where HEOR-driven evidence — structured to meet AOTMiT evidence requirements and EU HTA regulation standards — is increasingly decisive for market access success. The right Poland healthcare research partner must combine global methodology standards with deep AOTMiT/NFZ regulatory expertise and Polish-English bilingual field capability.
5 Healthcare Market Research Companies in Poland (2026)
Firms are assessed by use case and market positioning — select based on your research type, sector, and in-country requirements.
BioNixus
Best for: pharmaceutical U&A, KOL mapping, physician surveys, AOTMiT/NFZ HTA and market access support, HEOR, Polish KOL networks, and CEE regional strategy — Poland execution with global methodology standards
BioNixus is a global healthcare market research and insights firm headquartered in the USA with offices in the UK and Middle East, delivering specialist pharmaceutical and healthcare research across Poland and the wider CEE region. With 15+ years of experience serving 48+ global clients across 17+ countries, BioNixus brings deep Poland market expertise to every engagement — from Polish physician and KOL surveys to AOTMiT-aligned HTA evidence generation and NFZ payer research. BioNixus is fluent in Poland's healthcare regulatory and reimbursement landscape: AOTMiT HTA assessment methodology, MZ pricing procedures, NFZ reimbursement list dynamics, URPL registration processes, and EU HTA Regulation alignment for joint clinical assessments. The firm recruits across Poland's substantial specialist physician community and maintains established relationships with Polish KOLs across oncology, cardiology, rare diseases, and other high-value therapeutic areas. HEOR designed to meet AOTMiT evidence requirements, NFZ payer stakeholder research, and CEE regional market intelligence are core Poland capabilities that position BioNixus as the preferred full-service healthcare research partner for pharmaceutical and biotech companies operating in or entering the Polish market.
Key strengths
- Pharmaceutical U&A, brand tracking, and market access research in Poland and CEE
- AOTMiT HTA evidence generation and MZ/NFZ payer research support
- Physician surveys and KOL mapping across Polish specialist networks
- HEOR, patient journey, and health economics research for AOTMiT submissions
- NFZ payer research and Polish reimbursement list access strategy
- EU HTA Regulation alignment and CEE regional market intelligence
IQVIA Poland
Best for: IMS Poland pharma prescription data, Polish RWE, sales force effectiveness, and URPL/AOTMiT regulatory analytics
IQVIA has a Poland presence with Warsaw offices, providing healthcare data, analytics, and clinical research services to pharmaceutical companies in the Polish market. Their Poland prescription data (IMS Poland heritage), AOTMiT regulatory intelligence, and real-world evidence capabilities are used for commercial launch planning and market access strategy. IQVIA Poland supports technology-enabled clinical trials and regulatory strategy through URPL and EMA-aligned study designs. Their primary strength lies in pharmaceutical data and analytics at scale rather than qualitative or stakeholder-driven primary research.
Key strengths
- Poland prescription data and pharmaceutical audit (IMS Poland heritage)
- AOTMiT/URPL regulatory intelligence and Polish RWE
- Technology-enabled clinical trial and CRO services in Poland
- Sales force effectiveness and commercial analytics for Polish market
Ipsos Healthcare Poland
Best for: large-scale quantitative and qualitative healthcare research, HCP and patient surveys in Poland
Ipsos operates a healthcare research capability in Poland as part of its broader European network, delivering qualitative and quantitative studies for pharmaceutical and consumer health clients. Their Poland capability covers physician and patient surveys, message testing, concept evaluation, and therapy area landscape studies. Ipsos Healthcare Poland leverages the broader Ipsos Poland infrastructure for large-scale fieldwork and is an established name for multinational pharmaceutical clients requiring standardised European methodologies with Polish local execution and Polish-language instruments.
Key strengths
- Large-scale HCP and patient quantitative surveys in Poland
- Qualitative focus groups and in-depth interviews with Polish specialists
- Message testing and concept evaluation for Polish pharmaceutical market
- Standardised European pharmaceutical research methodologies
Kantar (Poland/CEE)
Best for: patient research, consumer health tracking, health behaviour studies, and brand health across Poland and CEE
Kantar serves the Polish and broader CEE market through its European research network, combining consumer research infrastructure with healthcare capability. Their primary strengths in Poland lie in patient research, consumer health tracking, and health behaviour studies — particularly valuable for OTC and consumer health brands. Kantar Poland is less focused on specialist pharmaceutical primary research and AOTMiT HTA support than dedicated pharma research agencies, but their Polish consumer panel and longitudinal tracking capabilities provide value for consumer health category research.
Key strengths
- Polish and CEE patient research and health behaviour tracking
- Consumer health and OTC product research for Poland
- Large European consumer panel including Polish respondents
- Brand health and marketing effectiveness for Polish healthcare brands
Euromonitor International
Best for: syndicated Poland market sizing, country reports, competitive landscape intelligence, and CEE category forecasts for consumer health
Euromonitor International provides syndicated market intelligence for Poland across healthcare, consumer health, and consumer goods categories. Their Passport database offers market sizing, five-year forecasts, and competitive intelligence for OTC healthcare, personal care, and wellness categories specific to the Polish and CEE markets. Euromonitor does not conduct custom primary research or AOTMiT-aligned HTA evidence work — their value lies in standardised market data for Poland market entry assessment, category benchmarking, and CEE competitive intelligence.
Key strengths
- Syndicated Poland market data and country reports
- Consumer health and OTC category coverage for Polish and CEE markets
- Five-year market forecasts and trend analysis
- Competitive landscape and company profiling for CEE region
Poland Healthcare Market Research Capabilities Comparison
| Capability | BioNixus | IQVIA Poland | Ipsos Healthcare | Kantar Poland | Euromonitor |
|---|---|---|---|---|---|
| Pharmaceutical primary research (qual + quant) | Full-service | Selective / analytics-led | Full-service | Limited pharma focus | None (syndicated only) |
| AOTMiT HTA support and NFZ payer research | Core capability | Analytics / regulatory data | Partial | Limited | No |
| Physician and KOL recruitment (Poland) | Yes | Yes (data-driven) | Yes | Limited | No |
| HEOR and outcomes research | Yes | Core capability | Partial | No | No |
| NFZ reimbursement and MZ pricing research | Yes | Partial | Partial | No | No |
| CEE regional strategy | Yes | Yes | Yes | Yes (consumer focus) | Country reports only |
Key Considerations for Poland Healthcare Market Research
AOTMiT HTA Assessment and NFZ Reimbursement Process
AOTMiT (Agencja Oceny Technologii Medycznych i Taryfikacji) conducts HTA assessments that form the foundation of Poland's pharmaceutical reimbursement decisions. AOTMiT's assessments evaluate clinical effectiveness, safety, and cost-effectiveness, and are reviewed by the Consultative Council (Rada Przejrzystości) before the Ministry of Health (MZ) makes final reimbursement and pricing decisions. NFZ (Narodowy Fundusz Zdrowia — National Health Fund) is the public payer that implements MZ reimbursement decisions and manages pharmacist dispensing reimbursement. Healthcare research buyers must ensure their HEOR and evidence generation aligns with AOTMiT's methodological guidelines and the EU HTA Regulation joint clinical assessment standards that increasingly apply to new oncology and ATMP products.
Poland as the CEE Pharmaceutical Hub
Poland is the largest pharmaceutical market in Central and Eastern Europe and functions as the primary regional hub for many multinational pharmaceutical companies' CEE strategies. Warsaw hosts major pharmaceutical regional headquarters and serves as the launch reference market for CEE rollouts. Poland's clinical trial activity is among the highest in CEE, supported by URPL's regulatory alignment with EMA standards and a large network of investigator sites across academic medical centres and hospital networks. Pharmaceutical companies frequently use Poland market research findings as a proxy for broader CEE market dynamics, making Poland-based HEOR and KOL evidence particularly strategically valuable.
HEOR and HTA Research Demand in Poland
Poland's AOTMiT HTA framework creates strong demand for health economics and outcomes research (HEOR) in the pharmaceutical sector. AOTMiT requires robust cost-effectiveness analyses, budget impact models, and systematic literature reviews as part of reimbursement dossiers. The EU HTA Regulation's joint clinical assessment requirements — applying to centralised procedure oncology and ATMP medicines from 2025 — further increase the HEOR evidence burden. Additionally, Poland's growing biosimilars sector, driven by NFZ tendering and reference pricing policies, creates competitive intelligence and formulary positioning research needs. Research partners with AOTMiT-aligned HEOR capability and Polish healthcare economic modelling expertise provide the most value for pharmaceutical market access in Poland.
Frequently Asked Questions
What are the best healthcare market research companies in Poland?
Leading healthcare market research companies in Poland include BioNixus, IQVIA Poland, Ipsos Healthcare Poland, Kantar Poland, and Euromonitor International. BioNixus is a global healthcare market research firm with Poland and CEE execution capability, covering pharmaceutical primary research, AOTMiT HTA support, NFZ payer research, physician surveys, KOL mapping, and HEOR.
How much does healthcare market research cost in Poland?
Custom healthcare market research in Poland typically ranges from €10,000 to €55,000 per project depending on methodology, therapeutic area, and scope. Qualitative KOL advisory boards typically cost €12,000–€30,000, while large-scale quantitative physician surveys or HEOR studies may reach €35,000–€70,000+. AOTMiT-aligned HTA evidence packages — including cost-effectiveness analyses and budget impact models — vary in cost based on complexity and data requirements.
Which company is best for AOTMiT HTA support and payer research in Poland?
BioNixus specialises in AOTMiT-aligned healthcare market research including payer qualitative interviews with NFZ and MZ stakeholders, Polish HCP evidence generation, and HEOR designed to meet AOTMiT methodology requirements. Their understanding of AOTMiT assessment processes, MZ pricing dynamics, and EU HTA Regulation joint clinical assessment standards positions them as a specialist partner for Poland pharmaceutical market access evidence.
How do I recruit physicians for market research studies in Poland?
Physician recruitment in Poland requires established professional networks across academic medical centres (academic hospitals — szpitale kliniczne), regional hospitals, and primary care networks (POZ — Podstawowa Opieka Zdrowotna). BioNixus maintains Poland physician and KOL recruitment networks across major therapeutic areas including oncology, haematology, rare diseases, and cardiology. Many Polish specialists are fluent in English, particularly those active in clinical research and international conferences.
What is AOTMiT and why does it matter for pharmaceutical companies in Poland?
AOTMiT (Agencja Oceny Technologii Medycznych i Taryfikacji) is Poland's Health Technology Assessment and Tariff Agency, responsible for evaluating the clinical and economic evidence for new medicines seeking reimbursement on the Polish NFZ list. AOTMiT's assessment is a prerequisite for MZ reimbursement decisions and NFZ listing. For pharmaceutical companies, a positive AOTMiT assessment — supported by robust cost-effectiveness analyses and Polish-specific real-world evidence — is critical for achieving broad public market access through the NFZ reimbursement system.
How does the NFZ reimbursement system work in Poland?
The NFZ (Narodowy Fundusz Zdrowia — National Health Fund) manages Poland's public health insurance and pharmaceutical reimbursement. Following AOTMiT HTA assessment, the Ministry of Health issues reimbursement decisions including price negotiations with manufacturers. Medicines are listed on the reimbursement list at negotiated prices and co-payment levels set by MZ. NFZ-reimbursed medicines must be prescribed generically or by approved brand names at listed prices. The reimbursement list is updated every three months, requiring ongoing market access monitoring.
What is the Polish pharmaceutical market size?
Poland's pharmaceutical market is valued at over €10 billion, making it the largest in Central and Eastern Europe. The market combines multinational brands with a significant domestic generic manufacturing sector led by Polpharma, Adamed, and Gedeon Richter Poland. Poland's EU membership ensures EMA regulatory alignment, and the country's growing biosimilars sector — driven by NFZ tendering policies — creates active competitive dynamics. Poland is also one of Europe's most active clinical trial markets, particularly in oncology and haematology.
Does BioNixus conduct healthcare market research in Poland?
Yes. BioNixus is a global healthcare market research firm with Poland and CEE delivery capability, serving pharmaceutical and biotech clients across the Polish market. Poland services include physician surveys, KOL mapping, AOTMiT HTA evidence research, HEOR, NFZ payer research, patient journey studies, and CEE regional market intelligence. Contact us to discuss your Poland healthcare research requirements.
Related Resources
Plan Healthcare Market Research in Poland
BioNixus delivers specialist healthcare market research across Poland and CEE — pharmaceutical primary research, AOTMiT HTA evidence, physician and KOL surveys, HEOR, NFZ payer research, and CEE regional market access strategy for pharma and biotech companies.
Request a Proposal